Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-05-16
2006-05-16
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C530S371000, C530S388850
Reexamination Certificate
active
07045129
ABSTRACT:
A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.
REFERENCES:
patent: 4849509 (1989-07-01), Thurin et al.
patent: 0 171 496 (1986-02-01), None
patent: 0 173 494 (1986-03-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 255 694 (1988-02-01), None
patent: 0 266 663 (1988-05-01), None
patent: 0 267 615 (1988-05-01), None
patent: 0 314 161 (1989-05-01), None
patent: 0 332 879 (1989-09-01), None
patent: 0 493 686 (1992-07-01), None
patent: 60-258128 (1985-12-01), None
patent: 86/01533 (1986-05-01), None
patent: 9109967 (1991-07-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
R. O. Dillman et al., “therapy of Chronic Lymphocytic Leukemia and Cutaneous T-Cell Lymphoma With T101 Monoclonal Antibody” J. Clin. Oncol., 2, 881, 1984.
A. F. LoBugulio et al., “Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody CO17-1A” J. Nat. Cancer Institute, 80, 932, 1988.
A. N. Houghton et al., “Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I Trial in patients with malignant melanoa”, Proc. Natl. Acad. Sci. USA, 82, 1242, 1985.
M. B. Khazaeli et al., “Phase I Trial of Multiple Large doses of Murine Monoclonal antibody CO17-1A” J. Nat. Cancer Institute, 80, 937, 1987.
N. S. Courtenay-Luck et al., “development of Primary and Secondary Immune Responses to Mouse Monoclonal Antibodies used in the Diagnosis and Therapy of Malignant Neoplasms” Cancer Res. 46, 6489, 1986.
A. F. LoBuglio et al., “Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response” Proc. Natl. acad. Sci. USA, 86, 422, 1989.
B. M. Mueller et al., “Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody” J. Immuno., 144, 1382, 1990.
C.S., Pukel et al., GD3, A Prominent Ganglioside of Human Melanoma, J. Exp. Med., 155, 1133, 1982.
E. Nudelman et al., Characterization of Human Melanoma-associated Ganglioside Antigen Defined by a Monoclonal Antibody, 4.2% J. Biol. Chem. 257, 12752, 1982.
J. A. Werkmeister et al., “Fluctuations in the Expression of an Glycolipid antigen Associated with Differentiation of Melanoma Cells Monitored by a Monoclonal Antibody, Leo Mel 3” Cancer Res. 47, 225, 1987.
M.-Y. Yeh et al., “A Cell-Surface Antigen Which is Present in the Ganglioside Franction and Shared By Human Melanomas” Int. J. Cancer, 29, 269, 1982.
S. L. Morrison et al., “Chimeric human antibody molecules : Mouse antigen-binding domains with human constant region domains” Proc. Natl. Acad. Sci. USA, 81, 6851, 1984.
K. Kameyama et al., “Convenient plasmid vecotrs for contruction of chimeric mouse/human antibodies” FEBS Letters, 244, 301, 1989.
S. D. Gillies et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes” J. Immunol. Method, 125, 191, 1989.
L. Riechmann et al., “Reshaping human antibodies for therapy” Nature, 332, 323, 1988.
H. Miyaji et al., “Expression of human beta-interferon in Namalwa KJM-1 which was adapted to serum-free medium” Cytotechnology, 3, 133, 1990.
T. Mizumi et al., “A New SV40-Based Vector Developed for cDNA Expression in Animal Cells” J. Biochem. 101, 1307, 1987.
Y. Kuwana et al., “Expression of Chimeric Receptor Composes of Immunoglobulin-Derived V Resions and T-Cell Receptor-Derived C Regions” Biochem. Biophys. Res. Commun., 149, 960, 1987.
Y. Kuwana et al., “Production of the constant domain of murine T-cell receptor β-chain inEscherichia coli” FEBS Letters, 219, 360, 1987.
S. Subramani et al., “Expression of the Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus 40 Vecotrs” Mol. Cell. Biol. 1, 854, 1981.
W. Roeder et al., “Linkage of the four γ subclass heavy chain genes” Proc. Natl. Acad. Sci. USA, 78 474, 1981.
H. Sakano et al., “Sequences at the somatic recombination sites of immunoglobulin light-chein genes” Nature, 280, 288, 1979.
Barker et al., “Effect of a Chimeric Anti-Ganglioside GC2 Antibody on Cell-mediated Lysis of Human Neuroblastoma Cells”, Cancer Research 51(1):1440149 (1991).
Ritter et al., “Antibody Response to Immunization with Purified GD3 Ganglioside and GD3 Derivatives (Lactones, Amide and Gangliosidol) in the Mouse”, Immunobiol. 182(1):32-43 (1990).
Waldmann Science 252:1657-1661 1991.
Harris et al., TiB Tech 11:42-44 1993.
Queen et al., PNAS 86:10029-1033 1989.
Sonnino et al., The Molecular Immunology of Complex Charbohydrates Eds Wu & Adams Plenum Press New York 437-464 1988.
Paul, Fundamental Immunology, Chapter 8, p. 242 (1993).
Welte et al, The Journal of Immunology, Sep. 15, 1987, vol. 139, No. 6, pp 1763-1771.
Hanai Nobuo
Hasegawa Mamoru
Kuwana Yoshihisa
Miyaji Hiromasa
Shitara Kenya
Helms Larry R.
Kyowa Hakko Kogyo Co. Ltd.
LandOfFree
Method of treating cancer including administering a human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cancer including administering a human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cancer including administering a human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3535704